Mega diabetes drug to be cheaper soon

With Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news